Immutep Faces Nasdaq Bid-Price Warning but Retains Dual Listings

Immutep ( (IMMP) ) has issued an update.

On April 30, 2026, Immutep Limited disclosed that it received a notice from Nasdaq stating its American Depositary Shares no longer meet the exchange’s minimum bid price requirement of US$1.00, after trading below that threshold for 30 consecutive business days through April 24. The biotech remains listed and trading on Nasdaq and the ASX, but has 180 calendar days, until October 26, 2026, to regain compliance by lifting its ADS closing bid price to at least US$1.00 for ten consecutive business days, and said it will monitor its share price and consider options, highlighting a compliance risk that could unsettle some investors but does not immediately affect its listings.

If Immutep restores the bid price within the allotted period, Nasdaq will confirm renewed compliance, while failure to do so could trigger further actions under Nasdaq rules, including potential delisting proceedings. The company emphasised that the Nasdaq notification has no immediate impact on trading of its ordinary shares on the ASX and pledged to keep the market informed of material developments under its continuous disclosure obligations, underscoring management’s focus on maintaining dual listings as it advances its clinical pipeline.

The most recent analyst rating on (IMMP) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.

Spark’s Take on IMMP Stock

According to Spark, TipRanks’ AI Analyst, IMMP is a Underperform.

The score is primarily held down by weak financial performance, including persistent losses and negative operating/free cash flow. Technicals add further pressure due to a broader downtrend and negative MACD, though near-oversold RSI/Stoch modestly offsets this. Valuation is also constrained by a negative P/E and no dividend yield data.

To see Spark’s full report on IMMP stock, click here.

More about Immutep

Immutep Limited is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases, with a focus on therapeutics targeting Lymphocyte Activation Gene-3 (LAG-3). The company leverages its LAG-3 expertise to create treatments that can either stimulate or suppress the immune system, aiming to deliver innovative options for patients while maximising value for shareholders.

Average Trading Volume: 15,413,575

Technical Sentiment Signal: Sell

Current Market Cap: $62.62M

For an in-depth examination of IMMP stock, go to TipRanks’ Overview page.